erythromycin has been researched along with cimetidine in 50 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (10.00) | 18.7374 |
1990's | 10 (20.00) | 18.2507 |
2000's | 18 (36.00) | 29.6817 |
2010's | 16 (32.00) | 24.3611 |
2020's | 1 (2.00) | 2.80 |
Authors | Studies |
---|---|
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
Endou, H; Kobayashi, Y; Ohshiro, N; Sasaki, T; Sekine, T; Shibusawa, A; Tokuyama, S; Yamamoto, T | 1 |
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
Dansette, PM; Fontana, E; Poli, SM | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Pratim Roy, P; Roy, K | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Guo, HF; Jin, J; Li, ZR; Liu, ZY; Xie, ZS; Xue, ST; Yi, H; Zhang, L | 1 |
Gordon, T; Hamilton, RA | 1 |
Hopkins, S | 1 |
Foulds, G; Gerber, N; Henry, EB; Hilligoss, DM | 1 |
Baciewicz, AM | 1 |
Debreczeni, LA; Herjavecz, I; Szeitz, A | 1 |
Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A | 1 |
Armstrong, JA; Goodwin, CS; Wee, SH; Wilson, DH | 1 |
D'Arcy, PF | 1 |
George, C; Mogford, N; Pallett, A | 1 |
Buters, JT; Friedman, FK; Koley, AP; Markowitz, A; Robinson, RC | 1 |
Ring, BJ; Wrighton, SA | 1 |
Csikó, G; Nijmeijer, SM; van Miert, AS; Witkamp, RF | 1 |
Taylor, D | 1 |
Pasco, J | 1 |
Hirayama, F; Iizumi, Y; Kawasaki, T; Koshio, H; Matsumoto, Y; Sato, K; Taniuchi, Y | 1 |
Douya, R; Mushiroda, T; Nagata, O; Takahara, E | 1 |
Crespi, CL; Fox, L; Hu, M; Steimel, DT; Stocker, P | 1 |
Iga, T; Katashima, M; Kotaki, H; Matsuo, H; Ohtani, H; Sawada, Y; Takedomi, S; Yamamoto, K; Yamano, K | 1 |
Hu, J; Liu, H; Liu, X; Wang, G; Xie, L | 1 |
Hayashi, Y; Helmi, AR; Khalil, WF; Motoyama, S; Sasaki, K; Shah, SS; Shimoda, M | 1 |
Di Nardo, G; Ferrero, S; Gilardi, G; Sadeghi, SJ | 1 |
4 review(s) available for erythromycin and cimetidine
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Carbamazepine drug interactions.
Topics: Carbamazepine; Cimetidine; Dextropropoxyphene; Drug Interactions; Erythromycin; Humans; Isoniazid; Lithium; Phenobarbital; Phenytoin; Primidone; Protein Binding; Troleandomycin; Valproic Acid; Warfarin | 1986 |
Pharmacokinetic interactions involving clozapine.
Topics: Anti-Bacterial Agents; Anticonvulsants; Antipsychotic Agents; Caffeine; Cimetidine; Clozapine; Drug Interactions; Erythromycin; Fluvoxamine; Humans; Risperidone; Selective Serotonin Reuptake Inhibitors | 1997 |
3 trial(s) available for erythromycin and cimetidine
Article | Year |
---|---|
Clinical toleration and safety of azithromycin.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Carbamazepine; Child; Child, Preschool; Cimetidine; Contraindications; Drug Evaluation; Drug Interactions; Eating; Erythromycin; Female; Humans; Male; Methylprednisolone; Middle Aged; Respiratory Tract Infections; Skin Diseases, Infectious; Theophylline; Urethritis; Uterine Cervicitis | 1991 |
The effects of an antacid or cimetidine on the serum concentrations of azithromycin.
Topics: Administration, Oral; Adult; Aluminum Hydroxide; Azithromycin; Cimetidine; Drug Combinations; Erythromycin; Humans; Magnesium Hydroxide; Male; Time Factors | 1991 |
Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state.
Topics: Adult; Cimetidine; Drug Interactions; Erythromycin; Fasting; Female; Food; Humans; Intestinal Absorption; Male; Random Allocation; Tablets; Tablets, Enteric-Coated | 1988 |
43 other study(ies) available for erythromycin and cimetidine
Article | Year |
---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
Topics: Amino Acid Sequence; Animals; Chromosome Mapping; Cloning, Molecular; Gene Expression Regulation; Mice; Molecular Sequence Data; Organic Anion Transporters, Sodium-Independent; RNA, Messenger; Sequence Homology, Amino Acid; Tissue Distribution | 2002 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes; Zebrafish | 2020 |
Incidence and cost of hospital admissions secondary to drug interactions involving theophylline.
Topics: Aged; Aged, 80 and over; Cimetidine; Ciprofloxacin; Drug Interactions; Erythromycin; Health Care Costs; Hospitalization; Hospitals, Veterans; Humans; Male; New York; Patient Admission; Theophylline | 1992 |
Effects of drugs on aminophylline elimination in rats.
Topics: Aminophylline; Animals; Behavior, Animal; Carbamazepine; Cimetidine; Drug Combinations; Drug Interactions; Erythromycin; Female; Half-Life; Phenobarbital; Phenytoin; Rats; Rats, Inbred Strains; Rifampin; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Campylobacter; Cell Wall; Cephalexin; Cimetidine; Clindamycin; Erythromycin; Metronidazole; Microscopy, Electron; Organometallic Compounds; Penicillin G | 1987 |
Early reports on drug interactions.
Topics: Acetaminophen; Amiodarone; Apazone; Aspirin; Carbamazepine; Chlordiazepoxide; Cimetidine; Coumarins; Drug Interactions; Erythromycin; Ethanol; Furosemide; Gentamicins; Humans; Levodopa; Lidocaine; Phenytoin; Prenylamine; Quinidine | 1983 |
Erythromycin deafness and cimetidine treatment.
Topics: Adult; Cimetidine; Drug Interactions; Erythromycin; Female; Hearing Loss, Bilateral; Humans; Male; Middle Aged | 1994 |
CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers.
Topics: Animals; Carbon Monoxide; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Ethinyl Estradiol; Humans; Kinetics; Mixed Function Oxygenases; Nifedipine; Protein Binding; Quinidine; Recombinant Proteins; Spodoptera; Substrate Specificity; Testosterone; Time Factors; Transfection; Warfarin | 1995 |
Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.
Topics: Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Nizatidine | 1994 |
Tiamulin selectively inhibits oxidative hepatic steroid and drug metabolism in vitro in the pig.
Topics: Animals; Anti-Bacterial Agents; Cimetidine; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; Diterpenes; Erythromycin; Ethylmorphine; Hydroxylation; Ketoconazole; Male; Microsomes, Liver; Oxidoreductases; Oxidoreductases, N-Demethylating; Swine; Testosterone | 1994 |
What has the patient been taking?
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chlorothiazide; Cimetidine; Diagnosis, Differential; Diuretics; Electrocardiography; Electrolytes; Erythromycin; Female; Histamine H1 Antagonists; Humans; Long QT Syndrome; Sodium Chloride Symporter Inhibitors; Terfenadine; Torsades de Pointes | 1998 |
Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Anticoagulants; Anticonvulsants; Antifibrinolytic Agents; Blood Coagulation; Carbamazepine; Cimetidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Male; Mice; Mice, Inbred ICR; Partial Thromboplastin Time; Phenytoin; Piperidines; Prothrombin Time; Rifampin; Sulfonamides; Thromboembolism; Thromboplastin; Vitamin K 1; Warfarin | 1998 |
The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate.
Topics: Administration, Oral; Animals; Antiemetics; Area Under Curve; Benzamides; Benzyl Compounds; Cimetidine; Cisapride; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dealkylation; Enzyme Stability; Erythromycin; Hot Temperature; Isoenzymes; Ketoconazole; Male; Microsomes, Liver; Mixed Function Oxygenases; Morpholines; Oxygen; Oxygenases; Rats; Rats, Sprague-Dawley | 2000 |
Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression.
Topics: Animals; Atenolol; Biological Transport; Cell Line; Cell Membrane Permeability; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Complementary; Erythromycin; Glucose; Humans; Mammals; Mannitol; Mixed Function Oxygenases; Pharmaceutical Preparations; Phenylalanine; Propranolol; Recombinant Proteins; Testosterone; Tumor Cells, Cultured; Verapamil | 2000 |
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Topics: Anesthetics, Intravenous; Animals; Aryl Hydrocarbon Hydroxylases; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Intestinal Absorption; Itraconazole; Kinetics; Liver; Male; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Portal Vein; Protein Binding; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2001 |
Possible multiple transporters were involved in hepatobiliary excretion of antofloxacin in rats.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bile; Biological Transport; Cimetidine; Cyclosporine; Diclofenac; Enzyme Inhibitors; Erythromycin; Liver; Male; Membrane Transport Proteins; Ofloxacin; Probenecid; Rats; Rats, Sprague-Dawley; Uricosuric Agents | 2007 |
Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Cats; Cimetidine; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Female; Half-Life; Hypnotics and Sedatives; Ketoconazole; Microsomes, Liver; Midazolam | 2009 |
Drug-drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4.
Topics: Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diclofenac; Drug Interactions; Electrochemical Techniques; Electrodes; Enzyme Inhibitors; Enzymes, Immobilized; Erythromycin; Inhibitory Concentration 50; Ketoconazole; Polyethylenes; Quaternary Ammonium Compounds; Quinidine | 2012 |